AzTrials
AzTrials

Low Ovarian ReserveFLUSHINGNCT07270081

Follicular Flushing Using Double Lumen Needle Versus Direct Aspiration in Low Prognosis Patients According to the POSEIDON Criteria

A study testing follicular flushing and follicular aspiration in people with Low Ovarian Reserve and Poor Response to Ovulation Induction Poseidon Type IV, run by Instituto Bernabeu at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a prospective, randomized, controlled clinical trial designed to evaluate whether follicular flushing increases the number of cumulus-oocyte complexes (COCs) retrieved compared to single aspiration in patients with poor ovarian response belonging to Poseidon groups 3 and 4. Read more about this study

Who is it for?
Ages Up to 43 years, women only
What is being tested?
follicular flushing and follicular aspiration
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteSpain
Study dates
1 Jan 2026to 1 Apr 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 43 years
  • Women only
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Pacientes con baja respuesta ovárica grupos POSEIDON 3 y 4 (< 35 años y RFA <5 y/o AMH < 1.2 ng/ml o > 35 años≥ 35 años y RFA <5 o AMH <1.2 ng/mL respectivamente)
  • Pacientes menores o igual a 43 años.
  • Índice de Masa Corporal (IMC) de 18-35 kg/m2
  • Estimulación ovárica para ICSI
  • Presencia y accesibilidad de ambos ovarios.
  • Ausencia de patología ovárica
  • Cuando se cumplan los criterios de desencadenamiento para la maduración final del ovocito, cada ovario debe contener al menos un folículo mayor o igual a 14 mm.
  • Haber dado su consentimiento por escrito.

Who cannot join

  • Presence of a single ovary.
  • Presence of ovarian pathology.
  • Use of conventional IVF as the fertilization method.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Instituto Bernabeu

    Alicante, Alicante, 03016

Other trials in Spain

About this study

This is a prospective, randomized, controlled clinical trial designed to evaluate whether follicular flushing increases the number of cumulus-oocyte complexes (COCs) retrieved compared to single aspiration in patients with poor ovarian response belonging to Poseidon groups 3 and 4.

A total of 40 patients with poor ovarian response belonging to Poseidon groups 3 and 4 will be included. In each patient, one ovary will be randomized to the study technique (follicular flushing), and the other ovary will be randomized to the control technique (single aspiration).

Read the detailed description

This is a prospective, randomized, controlled clinical study designed to evaluate the effect of follicular flushing on the number of cumulus-oocyte complexes (COCs) retrieved, compared to single aspiration, in patients with poor ovarian response classified as Poseidon groups 3 and 4.

A total of 40 patients will be included. All participants will receive a standardized stimulation protocol consistent with current practice for patients diagnosed with low ovarian reserve. After meeting all inclusion criteria, controlled ovarian stimulation will begin within the first four days of the menstrual cycle, using an antagonist protocol in all cases.

Starting on the 6th day of ovarian stimulation, daily administration of a GnRH antagonist at a dose of 0.25 mg (Ganirelix® or Cetrorelix®) will be initiated. Final oocyte maturation will be triggered once at least one follicle reaches a diameter of ≥17 mm, using either 250 μg of recombinant hCG (Ovitrelle®; Merck Serono) or 0.2 mg of triptorelin acetate (Decapeptyl®), or a double trigger. Oocyte retrieval will be performed 36 hours after triggering final oocyte maturation.

On the day of oocyte retrieval, randomization will be performed using a computer-generated randomization list. In each patient, one ovary will be randomly assigned to the control group (single aspiration), and the contralateral ovary will be assigned to the study group (follicular flushing). Simple random allocation will be used. Each patient will be allowed to participate in the study only once.

Oocyte retrieval procedures will be performed by four trained physicians to evaluate the reproducibility and generalizability of the technique. Follicles will be aspirated using 17G needles in both groups. For follicular flushing, the same needle model used for single aspiration (Cook) will be employed. To eliminate dead space, the needle will be prefilled with flushing medium before beginning the procedure. Aspiration pressure will be maintained at 190 mmHg during oocyte retrieval.

In the single aspiration group, after aspirating all follicles, the needle will be rinsed with flushing medium to minimize the risk of oocyte retention inside the needle.

In the follicular flushing group, if no cumulus-oocyte complex (COC) is recovered during the initial aspiration, follicular flushing will be repeated until a COC is obtained, up to a maximum of three flushes. After three flushes, if no COC is retrieved, the procedure will be completed by rinsing with flushing medium to prevent possible oocyte retention within the needle.

The embryologist will immediately inform the physician performing the oocyte retrieval whether a COC has been recovered, in order to determine whether to continue flushing or proceed to the next follicle (open flushing technique).

The duration of the procedure will be recorded from needle insertion to its withdrawal for each ovary in both groups.

Being tested
follicular flushing, follicular aspiration
Keywords
Follicular flushing, Poseidon 3 and 4, Poor responder, low ovarian reserve

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • follicular flushingProcedure or surgery

    Follicles will be aspirated using 17G needles of the same gauge in both groups. For follicular flushing, the same type of needle used for single aspiration (Cook) will be employed. To eliminate dead space, the needle will be prefilled with flushing medium before starting the procedure. Aspiration pressure will be maintained at 190 mmHg during oocyte retrieval. In the follicular flushing group, if no cumulus-oocyte complex (COC) is recovered during the initial aspiration, follicular flushing will be performed until a COC is obtained, up to a maximum of three times. After three flushes, if no COC is retrieved, the procedure will be completed by rinsing with flushing medium to minimize the possibility of oocyte retention within the needle.

  • follicular aspirationProcedure or surgery

    In the single aspiration group, after aspirating all follicles, the needle will be rinsed with flushing medium to prevent the possibility of oocyte retention within the needle.

Study groups in NCT07270081
Study groupRoleWhat they receive
Single Aspiration ArmActive comparatorOocytes will be retrieved from one ovary using single follicular aspiration
Receives: Procedure: follicular aspiration
Follicular Flushing ArmExperimentalOocytes will be retrieved from the contralateral ovary using follicular flushing, with up to three flushes per follicle if no cumulus-oocyte complex is obtained initially
Receives: Procedure: follicular flushing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. number of cumulus-oocyte complexes

    number of cumulus-oocyte complexes (COCs) retrieved after each aspiration

    Measured: During the egg retrieval

Secondary outcomes (4)
  1. Oocyte recovery rate

    number of oocytes retrieved / number of follicles ≥11 mm on the day of final oocyte maturation trigger

    Measured: day of the egg retrieval

  2. Fertilization rate

    number of 2PNs / number of MII oocytes

    Measured: 1 day after the egg retrieval

  3. Empty follicle rate

    zero oocytes retrieved / follicles punctured

    Measured: day of the egg retrieval

  4. Procedure time

    calculated from needle insertion to its withdrawal for each ovary

    Measured: In seconds from needle insertion to its withdrawal for each ovary

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Dec 2025
  2. Study start1 Jan 2026
  3. Primary completion1 Apr 2026
  4. Study completion1 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Model description
Each participant will serve as her own control. One ovary will be randomized to single aspiration and the contralateral ovary to follicular flushing.
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07270081
Sponsor's protocol ID
MR47
Acronym
FLUSHING
Status last verified
Apr 2026
First submitted
17 Nov 2025
Last updated
14 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing follicular flushing and follicular aspiration in people with Low Ovarian Reserve and Poor Response to Ovulation Induction Poseidon Type IV, run by Instituto Bernabeu at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 14 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

number of cumulus-oocyte complexes (time frame: During the egg retrieval). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in